lorcaserin
Sign in to saveAlso known as APD-356, Belviq®, Lorqess
Lorcaserin, marketed under the brand name Belviq, was a weight-loss drug developed by Arena Pharmaceuticals. It reduces appetite by activating the 5-HT2C serotonin receptor in the hypothalamus, a region of the brain which is known to control appetite. It was approved in 2012, and in 2020 was removed from the market in the United States due to an increased risk of cancer detected in users of Belviq.
Wikidata facts
- Mass
- 195.081477
Show 5 more facts
- chemical formula
- C₁₁H₁₄ClN
- Commons category
- Lorcaserin
- isomeric SMILES
- C[C@H]1CNCCC2=C1C=C(C=C2)Cl
- canonical SMILES
- CC1CNCCC2=C1C=C(C=C2)Cl
- World Health Organisation international non-proprietary name
- lorcaserin
via Wikidata · CC0
~8 min read
Article
18 sectionsContents
- Medical uses
- Side effects
- Overdose
- Pharmacology
- Pharmacodynamics
- Pharmacokinetics
- Chemistry
- History
- Approval history
- Society and culture
- Legal status
- Canada
- United States
- Research
- Epilepsy
- See also
- References
- External links
Lorcaserin, marketed under the brand name Belviq, was a weight-loss drug developed by Arena Pharmaceuticals. It reduces appetite by activating the 5-HT2C serotonin receptor in the hypothalamus, a region of the brain which is known to control appetite. It was approved in 2012, and in 2020 was removed from the market in the United States due to an increased risk of cancer detected in users of Belviq.
== Medical uses == Lorcaserin was used long term for weight loss in those who are obese.